PMID- 17539021
OWN - NLM
STAT- MEDLINE
DCOM- 20080110
LR  - 20220316
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 50
IP  - 2
DP  - 2008 Feb
TI  - Treatment of Wilms tumor relapsing after initial treatment with vincristine, 
      actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study 
      Group.
PG  - 236-41
AB  - OBJECTIVE: We evaluated the use of alternating cycles of 
      cyclophosphamide/etoposide and carboplatin/etoposide in children entered on 
      National Wilms Tumor Study (NWTS)-5 who were diagnosed between August 1, 1995 and 
      May 31, 2002 and who relapsed after chemotherapy with vincristine, actinomycin D, 
      and doxorubicin (VAD) and radiation therapy (DD-4A). PATIENTS AND METHODS: One 
      hundred three patients who relapsed or had progressive disease after initial VAD 
      chemotherapy and radiation therapy were registered on stratum C of the NWTS-5 
      Relapse protocol. Twelve patients were not evaluable: five due to insufficient 
      data, six due to major protocol violations, and one for refusal of therapy. Among 
      the 91 remaining patients, 14 with stage V Wilms tumor (WT), 1 with contralateral 
      relapse, and 16 who did not achieve a complete response (CR) to the initial 
      three-drug chemotherapy were not included in this analysis. Relapse treatment 
      included alternating courses of the drug pairs cyclophosphamide/etoposide and 
      carboplatin/etoposide, surgery, and radiation therapy. RESULTS: The outcomes of 
      60 patients were analyzed. The lung was the only site of relapse for 33 patients; 
      other sites of relapse included the operative bed, the abdomen, and liver. 
      Four-year event-free survival (EFS) and overall survival (OS) were 42.3 and 48.0% 
      respectively for all patients and were 48.9 and 52.8% for those who relapsed in 
      the lungs only. Thrombocytopenia was the most frequent toxicity. CONCLUSION: 
      These results demonstrate that approximately one-half of children with unilateral 
      WT who relapse after initial treatment with VAD and radiation therapy can be 
      successfully retreated.
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Malogolowkin, Marcio
AU  - Malogolowkin M
AD  - Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, 
      California, USA.
FAU - Cotton, Cecilia A
AU  - Cotton CA
FAU - Green, Daniel M
AU  - Green DM
FAU - Breslow, Norman E
AU  - Breslow NE
FAU - Perlman, Elizabeth
AU  - Perlman E
FAU - Miser, James
AU  - Miser J
FAU - Ritchey, Michael L
AU  - Ritchey ML
FAU - Thomas, Patrick R M
AU  - Thomas PR
FAU - Grundy, Paul E
AU  - Grundy PE
FAU - D'Angio, Giulio J
AU  - D'Angio GJ
FAU - Beckwith, J Bruce
AU  - Beckwith JB
FAU - Shamberger, Robert C
AU  - Shamberger RC
FAU - Haase, Gerald M
AU  - Haase GM
FAU - Donaldson, Milton
AU  - Donaldson M
FAU - Weetman, Robert
AU  - Weetman R
FAU - Coppes, Max J
AU  - Coppes MJ
FAU - Shearer, Patricia
AU  - Shearer P
FAU - Coccia, Peter
AU  - Coccia P
FAU - Kletzel, Morris
AU  - Kletzel M
FAU - Macklis, Roger
AU  - Macklis R
FAU - Tomlinson, Gail
AU  - Tomlinson G
FAU - Huff, Vicki
AU  - Huff V
FAU - Newbury, Robert
AU  - Newbury R
FAU - Weeks, Douglas
AU  - Weeks D
CN  - National Wilms Tumor Study Group
LA  - eng
GR  - CA-42326/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 80168379AG (Doxorubicin)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Carboplatin/administration & dosage
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Dactinomycin/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Drug Administration Schedule
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Kidney Neoplasms/*drug therapy/pathology/radiotherapy/surgery
MH  - Male
MH  - Neoplasm Staging
MH  - Recurrence
MH  - Wilms Tumor/*drug therapy/pathology/radiotherapy/surgery
EDAT- 2007/06/01 09:00
MHDA- 2008/01/11 09:00
CRDT- 2007/06/01 09:00
PHST- 2007/06/01 09:00 [pubmed]
PHST- 2008/01/11 09:00 [medline]
PHST- 2007/06/01 09:00 [entrez]
AID - 10.1002/pbc.21267 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2008 Feb;50(2):236-41. doi: 10.1002/pbc.21267.